Substance use during the COVID-19 pandemic: What is really happening?

Q3 Medicine Psychiatrike = Psychiatriki Pub Date : 2022-03-28 Epub Date: 2022-02-21 DOI:10.22365/jpsych.2022.072
Eleftherios Mellos, Thomas Paparrigopoulos
{"title":"Substance use during the COVID-19 pandemic: What is really happening?","authors":"Eleftherios Mellos, Thomas Paparrigopoulos","doi":"10.22365/jpsych.2022.072","DOIUrl":null,"url":null,"abstract":"<p><p>The COVID-19 pandemic is associated with increased levels of anxiety, fear, sadness, difficulty adjusting, symptoms of post-traumatic stress disorder and suicidality, both in the general population and specific subgroups. The presence of this type of psychopathology increases the risk of involvement with or worsens the use of addictive substances and alcohol as a maladaptive coping strategy.1 According to these data, people with substance use disorders are a population at high risk for COVID-19 infection and serious illness. Α large controlled retrospective case study in the US found that people with substance use disorders are significantly more vulnerable to COVID-19 and its complications (primarily those with opioid use disorder OR = 10.21 and with tobacco use disorder OR = 8.25), and that the course and outcome of the disease (hospitalization, death) was worse than in non-dependent individuals. The main culprits are increased physical co-morbidity (frequent respiratory and cardiovascular problems), poor health and living conditions, marginalization and difficulties in accessing health services. 2,3 Ιnternational epidemiological data during the first months of the pandemic regarding the use of addictive substances do not lead to safe conclusions. A cross-sectional online epidemiological study conducted on a sample of 36,538 adults from 21 European countries between April and July 2020 found an overall decrease in alcohol use, which was mainly attributed to the reduction of heavy episodic consumption, while at the same time an increase in alcohol consumption among people with severe alcohol use was recorded. Τhe use of cannabis and nicotine showed increasing trends, as well as the use of cocaine, but to a lesser extent, while the use of MDMA (ecstasy) showed a decrease.4 In a review of 45 cross-sectional studies conducted between December 2019 and November 2020, alcohol use was on the rise overall, despite geographical variations, as was the use of other addictive substances, cannabis in particular.5 It should be noted that those who increased alcohol use during quarantine were those exhibiting higher levels of negative emotionality mechanisms.6 In Greece, an online cross-sectional survey in April 2020 in the general population during the first lockdown showed a reduction in alcohol use (43.7% of alcohol users reduced or quit), a reduction in cannabis (67.3% quit), while 33.3% increased nicotine use. These changes were attributed to the limitation of alcohol availability, social distancing, changes in daily routine and income reduction.7,8 Also, wastewater samples from Athens, analyzed by the Laboratory of Analytical Chemistry of EKPA, showed a significant increase in the use of cocaine (67%), amphetamine (350%) and methamphetamine (37%), and a decrease in the use of MDMA (- 38%) during the first lockdown, compared to the corresponding period of the previous year.9 Analysis of wastewater samples from other European cities \"suggest that levels of use of most drugs appear generally lower during the initial lockdowns, but then appear to bounce back once lockdown was lifted. A comparison with 2019 appears to suggest similar overall consumption of most drugs, and in several cities possibly even higher levels, based on this data source. Exceptions here appear to be MDMA and methamphetamine, two drugs for which the levels observed in 2020 appear lower in most of the participating cities\".10,11 There were also changes in the locations of use of the substances, as with the periodic restrictions the use was transferred mainly at home and in open public spaces; in some cases, it was associated with increased intravenous use and cases of intoxication. Finally, intermittent difficulties in drug availability and trafficking have led users to search for other substances, increase experimentation and multidrug use, and make online purchases. In addition, there is concern about the increasing abuse of benzodiazepines, which are either diverted from therapeutic use or appear on the illicit market, often as new benzodiazepines.10,12 According to the European Monitoring Center for Drugs and Drug Addiction (EMCDDA), \"the drug market has been remarkably resilient to disruption caused by the pandemic\" … Drug trafficking has adapted to the new conditions with changes in routes and methods of trafficking, and by further enhancing the digital presence of the drug market… \"Any reductions in drug consumption seen during the initial lockdowns rapidly disappeared as social distancing measures were eased. In general terms, there appears to have been less consumer interest in drugs usually associated with recreational events, such as MDMA, and greater interest in drugs linked with home use. However, the easing of restrictions … during the summer was associated with a rebound in the levels of use\". Also, \"survey data suggest that those using drugs occasionally prior to COVID-19 may have reduced or even ceased their use during the pandemic, but more-regular users may have increased their drug consumption\".10 Measures taken to control the pandemic have reduced and modified the mental health and addiction treatment services provided. Although services have been adequately restored, there has initially been a 60% reduction in the availability and provision of detoxification services in Europe.13 Live contact, mainly at group level, was significantly reduced or stopped altogether for a long period, as well as the frequency of individual appointments. Therapeutic programs sought to respond to the new conditions using technology and telemedicine, providing online group support and psychotherapy. Substitution treatment programs have become more flexible by providing long-term pharmaceutical substitutes (take home) to prevent users from moving. There have also been facilitations in prescribing by treating physicians. Thus, the addicts' contact with the treatment process was maintained, but it was insufficient to meet their increased needs during this period. In conclusion, it should be noted that substance use appears to have an autonomous dynamism in relation to the pandemic and the consequent psychopathology, being in a \"loose\" causal relationship with it. Therefore, hasty and untimely generalizations should be avoided, and easy conclusions should not be drawn through extrapolations from previous socio-economic crises of different types or through partial spatiotemporal understandings, which are usually presented by the media in the form of negative alarming information.</p>","PeriodicalId":20741,"journal":{"name":"Psychiatrike = Psychiatriki","volume":"4 1","pages":"17-20"},"PeriodicalIF":0.0000,"publicationDate":"2022-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychiatrike = Psychiatriki","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22365/jpsych.2022.072","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/2/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

The COVID-19 pandemic is associated with increased levels of anxiety, fear, sadness, difficulty adjusting, symptoms of post-traumatic stress disorder and suicidality, both in the general population and specific subgroups. The presence of this type of psychopathology increases the risk of involvement with or worsens the use of addictive substances and alcohol as a maladaptive coping strategy.1 According to these data, people with substance use disorders are a population at high risk for COVID-19 infection and serious illness. Α large controlled retrospective case study in the US found that people with substance use disorders are significantly more vulnerable to COVID-19 and its complications (primarily those with opioid use disorder OR = 10.21 and with tobacco use disorder OR = 8.25), and that the course and outcome of the disease (hospitalization, death) was worse than in non-dependent individuals. The main culprits are increased physical co-morbidity (frequent respiratory and cardiovascular problems), poor health and living conditions, marginalization and difficulties in accessing health services. 2,3 Ιnternational epidemiological data during the first months of the pandemic regarding the use of addictive substances do not lead to safe conclusions. A cross-sectional online epidemiological study conducted on a sample of 36,538 adults from 21 European countries between April and July 2020 found an overall decrease in alcohol use, which was mainly attributed to the reduction of heavy episodic consumption, while at the same time an increase in alcohol consumption among people with severe alcohol use was recorded. Τhe use of cannabis and nicotine showed increasing trends, as well as the use of cocaine, but to a lesser extent, while the use of MDMA (ecstasy) showed a decrease.4 In a review of 45 cross-sectional studies conducted between December 2019 and November 2020, alcohol use was on the rise overall, despite geographical variations, as was the use of other addictive substances, cannabis in particular.5 It should be noted that those who increased alcohol use during quarantine were those exhibiting higher levels of negative emotionality mechanisms.6 In Greece, an online cross-sectional survey in April 2020 in the general population during the first lockdown showed a reduction in alcohol use (43.7% of alcohol users reduced or quit), a reduction in cannabis (67.3% quit), while 33.3% increased nicotine use. These changes were attributed to the limitation of alcohol availability, social distancing, changes in daily routine and income reduction.7,8 Also, wastewater samples from Athens, analyzed by the Laboratory of Analytical Chemistry of EKPA, showed a significant increase in the use of cocaine (67%), amphetamine (350%) and methamphetamine (37%), and a decrease in the use of MDMA (- 38%) during the first lockdown, compared to the corresponding period of the previous year.9 Analysis of wastewater samples from other European cities "suggest that levels of use of most drugs appear generally lower during the initial lockdowns, but then appear to bounce back once lockdown was lifted. A comparison with 2019 appears to suggest similar overall consumption of most drugs, and in several cities possibly even higher levels, based on this data source. Exceptions here appear to be MDMA and methamphetamine, two drugs for which the levels observed in 2020 appear lower in most of the participating cities".10,11 There were also changes in the locations of use of the substances, as with the periodic restrictions the use was transferred mainly at home and in open public spaces; in some cases, it was associated with increased intravenous use and cases of intoxication. Finally, intermittent difficulties in drug availability and trafficking have led users to search for other substances, increase experimentation and multidrug use, and make online purchases. In addition, there is concern about the increasing abuse of benzodiazepines, which are either diverted from therapeutic use or appear on the illicit market, often as new benzodiazepines.10,12 According to the European Monitoring Center for Drugs and Drug Addiction (EMCDDA), "the drug market has been remarkably resilient to disruption caused by the pandemic" … Drug trafficking has adapted to the new conditions with changes in routes and methods of trafficking, and by further enhancing the digital presence of the drug market… "Any reductions in drug consumption seen during the initial lockdowns rapidly disappeared as social distancing measures were eased. In general terms, there appears to have been less consumer interest in drugs usually associated with recreational events, such as MDMA, and greater interest in drugs linked with home use. However, the easing of restrictions … during the summer was associated with a rebound in the levels of use". Also, "survey data suggest that those using drugs occasionally prior to COVID-19 may have reduced or even ceased their use during the pandemic, but more-regular users may have increased their drug consumption".10 Measures taken to control the pandemic have reduced and modified the mental health and addiction treatment services provided. Although services have been adequately restored, there has initially been a 60% reduction in the availability and provision of detoxification services in Europe.13 Live contact, mainly at group level, was significantly reduced or stopped altogether for a long period, as well as the frequency of individual appointments. Therapeutic programs sought to respond to the new conditions using technology and telemedicine, providing online group support and psychotherapy. Substitution treatment programs have become more flexible by providing long-term pharmaceutical substitutes (take home) to prevent users from moving. There have also been facilitations in prescribing by treating physicians. Thus, the addicts' contact with the treatment process was maintained, but it was insufficient to meet their increased needs during this period. In conclusion, it should be noted that substance use appears to have an autonomous dynamism in relation to the pandemic and the consequent psychopathology, being in a "loose" causal relationship with it. Therefore, hasty and untimely generalizations should be avoided, and easy conclusions should not be drawn through extrapolations from previous socio-economic crises of different types or through partial spatiotemporal understandings, which are usually presented by the media in the form of negative alarming information.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
COVID-19大流行期间的物质使用:到底发生了什么?
在普通人群和特定亚群体中,COVID-19大流行与焦虑、恐惧、悲伤、适应困难、创伤后应激障碍症状和自杀倾向增加有关。这种类型的精神病理的存在增加了参与成瘾物质和酒精的风险或恶化了成瘾物质和酒精的使用,作为一种适应不良的应对策略根据这些数据,物质使用障碍患者是感染COVID-19和患严重疾病的高风险人群。Α美国的大型对照回顾性病例研究发现,物质使用障碍患者明显更容易受到COVID-19及其并发症的影响(主要是阿片类药物使用障碍OR = 10.21和烟草使用障碍OR = 8.25),并且疾病的过程和结果(住院、死亡)比非依赖个体更差。主要原因是身体合并症增加(呼吸道和心血管疾病频发)、健康和生活条件差、边缘化和难以获得保健服务。2,3 Ιnternational大流行最初几个月关于使用成瘾物质的流行病学数据并不能得出安全的结论。2020年4月至7月期间,对来自21个欧洲国家的36538名成年人进行的一项横断面在线流行病学研究发现,酒精使用量总体下降,这主要归因于间歇性大量饮酒的减少,与此同时,重度饮酒人群的酒精消费量有所增加。Τhe大麻和尼古丁的使用呈增加趋势,可卡因的使用也呈增加趋势,但程度较轻,而MDMA(摇头丸)的使用呈减少趋势在对2019年12月至2020年11月期间进行的45项横断面研究的回顾中,尽管存在地理差异,但酒精的使用总体上呈上升趋势,其他成瘾物质,特别是大麻的使用也是如此值得注意的是,那些在隔离期间酗酒的人是那些表现出更高水平的消极情绪机制的人在希腊,2020年4月在第一次封锁期间对普通人群进行的一项在线横断面调查显示,酒精使用量减少(43.7%的酒精使用者减少或戒烟),大麻使用量减少(67.3%戒烟),而尼古丁使用量增加了33.3%。这些变化归因于酒精供应的限制、社交距离、日常生活的变化和收入的减少。7,8此外,经EKPA分析化学实验室分析,来自雅典的废水样本显示,与去年同期相比,在第一次封锁期间,可卡因(67%)、安非他明(350%)和甲基苯丙胺(37%)的使用显著增加,MDMA的使用减少(- 38%)对其他欧洲城市废水样本的分析“表明,在最初的封锁期间,大多数药物的使用水平似乎普遍较低,但一旦封锁解除,药物的使用水平似乎又会反弹。”根据这一数据来源,与2019年的比较似乎表明,大多数药物的总体消费量相似,在一些城市甚至可能更高。这里的例外似乎是MDMA和甲基苯丙胺,这两种毒品在2020年观察到的水平在大多数参与城市似乎更低”。10,11这些物质的使用地点也发生了变化,由于定期限制,这些物质的使用主要转移到家中和开放的公共场所;在某些情况下,它与静脉注射增加和中毒有关。最后,药物供应和贩运方面的间歇性困难导致使用者寻找其他物质,增加试验和多种药物的使用,并进行网上购买。此外,令人关切的是苯二氮卓类药物的滥用日益增加,这些药物要么从治疗用途转移,要么经常作为新的苯二氮卓类药物出现在非法市场上。10,12根据欧洲毒品和吸毒成瘾监测中心(EMCDDA)的说法,“毒品市场对大流行病造成的破坏具有显著的弹性” .毒品贩运已经适应了新的情况,贩运路线和方法发生了变化,并进一步加强了毒品市场的数字化存在。"随着社会距离措施的放松,最初封锁期间出现的毒品消费减少迅速消失。总的来说,消费者似乎对通常与娱乐活动有关的药物(如MDMA)兴趣不大,而对与家庭使用有关的药物兴趣更大。然而,夏季限制的放松……与使用水平的反弹有关。” 此外,“调查数据表明,那些在COVID-19之前偶尔使用药物的人可能在大流行期间减少甚至停止使用药物,但更经常使用药物的人可能增加了药物消费量”为控制这一流行病而采取的措施减少和修改了所提供的精神健康和成瘾治疗服务。虽然服务已经充分恢复,但在欧洲,最初提供的解毒服务减少了60%。13主要是团体一级的现场接触大大减少或在很长一段时间内完全停止,个人预约的频率也减少了。治疗方案试图利用技术和远程医疗来应对新的情况,提供在线团体支持和心理治疗。替代治疗方案变得更加灵活,提供长期的药物替代品(带回家),以防止使用者移动。治疗医生在开处方方面也有所便利。因此,成瘾者与治疗过程保持联系,但不足以满足他们在此期间增加的需求。最后,应当指出,药物使用似乎与流行病及其造成的精神病理有一种自主的动态关系,与流行病有一种“松散的”因果关系。因此,应避免草率和不合时宜的概括,不应通过以往不同类型的社会经济危机的外推或通过片面的时空理解来轻易得出结论,这通常是媒体以负面警示信息的形式呈现的。 此外,“调查数据表明,那些在COVID-19之前偶尔使用药物的人可能在大流行期间减少甚至停止使用药物,但更经常使用药物的人可能增加了药物消费量”为控制这一流行病而采取的措施减少和修改了所提供的精神健康和成瘾治疗服务。虽然服务已经充分恢复,但在欧洲,最初提供的解毒服务减少了60%。13主要是团体一级的现场接触大大减少或在很长一段时间内完全停止,个人预约的频率也减少了。治疗方案试图利用技术和远程医疗来应对新的情况,提供在线团体支持和心理治疗。替代治疗方案变得更加灵活,提供长期的药物替代品(带回家),以防止使用者移动。治疗医生在开处方方面也有所便利。因此,成瘾者与治疗过程保持联系,但不足以满足他们在此期间增加的需求。最后,应当指出,药物使用似乎与流行病及其造成的精神病理有一种自主的动态关系,与流行病有一种"松散的"因果关系。因此,应避免草率和不合时宜的概括,不应通过以往不同类型的社会经济危机的外推或通过片面的时空理解来轻易得出结论,这通常是媒体以负面警示信息的形式呈现的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Psychiatrike = Psychiatriki
Psychiatrike = Psychiatriki Medicine-Medicine (all)
CiteScore
2.60
自引率
0.00%
发文量
37
期刊最新文献
A systematic review on the efficacy of CBT on pain and sexual function of vulvodynia. The evaluation of quality characteristics of the mental health services provided at the General Outpatient Psychiatry Clinic of the Eginition Hospital. Towards Precision ECT: A systematic review of epigenetic biomarkers in treatment-resistant depression. Timing and self distortions in psychosis: Is it an insula matter? Exposure and response of private practice psychiatrists in Greece to illicit substance use-related treatment requests: A cross-sectional survey.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1